Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 Combined With Bevacizumab as Second-line Treatment in Patients Metastatic CRC
NCT07355764Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Dec 2025
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 2 trial of trastuzumab rezetecan in colorectal cancer (CRC), sponsored by Peking Union Medical College Hospital. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07355764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07355764.